Comparison of ocular hypotensive actions of fixed combinations of brimonidine/timolol and dorzolamide/timolol

References

• Advanced Glaucoma Intervention Study. The Advanced Glaucoma Intervention Study (AGIS): the relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000;130:429-40
   PubMed Web of Science ®Google Scholar
• Chauhan BC, Mikelberg FS, Balaszi AG, et al. Canadian Glaucoma Study: risk factors for the progression of open-angle glaucoma. Arch Ophthalmol 2008;126:1030-6
   PubMed Web of Science ®Google Scholar
• Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 1998;126:487-97
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007;114:1965-72
   PubMed Web of Science ®Google Scholar
• European Glaucoma Society. Terminology and Guidelines for Glaucoma, 3rd edn. Savona, Italy: Editrice Dogma, 2008
   Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
   PubMed Web of Science ®Google Scholar
• Dunker S, Schmucker A, Maier H. Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol. Adv Ther 2007;24:376-86
   PubMed Web of Science ®Google Scholar
• Cox JA, Mollan SP, Bankart J, et al. Efficacy of antiglaucoma fixed combination therapy versus unfixed components in reducing intraocular pressure: a systematic review. Br J Ophthalmol 2008;92:729-34
   PubMed Web of Science ®Google Scholar
• Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging 2007;24:1007-16
   PubMed Web of Science ®Google Scholar
• Tabet R, Stewart WC, Feldman R, et al. A review of additivity to prostaglandin analogs: fixed and unfixed combinations. Surv Ophthalmol 2008;53(Suppl. 1):S85-92
   PubMedGoogle Scholar
• Goni FJ. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2005;15:581-90
   PubMed Web of Science ®Google Scholar
• Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 2006;124:1230-8
   PubMed Web of Science ®Google Scholar
• Lesk MR, Koulis T, Sampalis F, et al. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension. Ann Pharmacother 2008;42:498-504
   PubMed Web of Science ®Google Scholar
• Strohmaier K, Snyder E, DuBiner H, et al. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group. Ophthalmology 1998;105:1936-44
   PubMed Web of Science ®Google Scholar
• Ashburn FS, Jr Goldberg I, Kass MA. Compliance with ocular therapy. Surv Ophthalmol 1980;24:237-48
   PubMed Web of Science ®Google Scholar
• Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-7
   PubMed Web of Science ®Google Scholar
• Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?. Ophthalmology 2005;112:863-8
   PubMed Web of Science ®Google Scholar
• Sleath B, Robin AL, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology 2006;113:431-6
   PubMed Web of Science ®Google Scholar
• Zimmerman TJ, Zalta AH. Facilitating patient compliance in glaucoma therapy. Surv Ophthalmol 1983;28(Suppl):252-8
   PubMedGoogle Scholar
• Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol 2008;86:716-26
   PubMed Web of Science ®Google Scholar
• Craven ER, Walters TR, Williams R, et al. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2005;21:337-48
   PubMed Web of Science ®Google Scholar
• Konstas AG, Katsimpris IE, Kaltsos K, et al. Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components. Eye 2008;22:1391-7
   PubMed Web of Science ®Google Scholar
• Boyle JE, Ghosh K, Gieser DK, et al. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology 1999;106:10-16
   PubMed Web of Science ®Google Scholar
• Francis BA, Du LT, Berke S, et al. Comparing the fixed combination dorzolamide-timolol (Cosopt) to concomitant administration of 2% dorzolamide (Trusopt) and 0.5% timolol – a randomized controlled trial and a replacement study. J Clin Pharm Ther 2004;29:375-80
   PubMed Web of Science ®Google Scholar
• Hutzelmann J, Owens S, Shedden A, et al. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Br J Ophthalmol 1998;82:1249-53
   PubMed Web of Science ®Google Scholar
• Carrasco FC, Arias PA, Garcia Saenz MC, et al. [Efficiency of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers]. Arch Soc Esp Oftalmol 2004;79:163-8
   PubMedGoogle Scholar
• Simmons ST. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension. Clin Ther 2001;23:604-19
   PubMed Web of Science ®Google Scholar
• Solish AM, DeLucca PT, Cassel DA, et al. Dorzolamide/timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. J Glaucoma 2004;13:149-57
   PubMed Web of Science ®Google Scholar
• Sall KN, Greff LJ, Johnson-Pratt LR, et al. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. Ophthalmology 2003;110:615-24
   PubMed Web of Science ®Google Scholar
• Hatanaka M, Grigera DE, Barbosa WL, et al. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure. J Glaucoma 2008;17:674-9
   PubMed Web of Science ®Google Scholar
• Arcieri ES, Arcieri RS, Pereira AC, et al. Comparing the fixed combination brimonidine-timolol versus fixed combination dorzolamide-timolol in patients with elevated intraocular pressure. Curr Med Res Opin 2007;23:683-9
   PubMed Web of Science ®Google Scholar
• Advanced Glaucoma Intervention Study. The Advanced Glaucoma Intervention Study (AGIS): 3. Baseline characteristics of black and white patients. Ophthalmology 1998;105:1137-45
   PubMed Web of Science ®Google Scholar
• Friedman DS, Wilson MR, Liebmann JM, et al. An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol 2004;138:S19-31
   PubMed Web of Science ®Google Scholar
• Netland PA, Robertson SM, Sullivan EK, et al. Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension. Adv Ther 2003;20:149-63
   PubMed Web of Science ®Google Scholar
• Kitnarong N, Zhao Y, Netland PA, et al. Efficacy of latanoprost and timolol maleate in black and white patients. Adv Ther 2004;21:203-13
   PubMed Web of Science ®Google Scholar
• Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol 1991;109:1090-5
   PubMed Web of Science ®Google Scholar
• Nixon DR, Yan DB, Chartrand JP, et al. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy. Curr Med Res Opin 2009;25:1645-53
   PubMed Web of Science ®Google Scholar